Font Size:
a
A
A
Keyword [HER2-positive]
Result: 41 - 60 | Page: 3 of 6
41.
The Role And Mechanism Of EPHA5 In The Trastuzumab Resistance Of HER2-positive Breast Cancer
42.
Optimized Metformin And Trastuzumab Dosing Schedule Based On Circadian Dynamics Of Glucose Metabolism Overcome Trastuzumab Resistance In HER2-positive Gastric Cancer
43.
99m
Tc-Z
HER2:V2
Molecular Imaging And Its Value In Monitoring The Early Efficacy In HER2 Positive Tumors' Treatment
44.
Membrane Cholesterol Decreased Chemotherapy Sensitivity In HER2-positive Trastuzumab Resistant Gastric Cancer Via Upregulation Of ABCB1
45.
The Effect And Mechanism Of Aqueous Extract Of Myrrh On Proliferation,Migration,Invasion Of HER2-Positive Breast Cancer Cells SK-BR-3
46.
Expression Of MTDH,topo? In Pre-operative Neoadjuvant Chemotherapy Combined With Herceptin In Patients With HER2-positive Breast Cancer And Investigate The Prognosis
47.
Targeted Therapy Effect Of Z
HER2:V2
-pemetrexed For HER2-positive Lung Adenocarcinoma And It's Molecular Imaging Evaluation
48.
Involvement Of ER Stress In Mechanism Of Trastuzumab Resistance Occurrence And Transmission Of HER2-positive Gastric Cancer
49.
The Molecular Mechanism And Clinical Significance Of MICA/B Expression In HER2-positive Breast Cancer
50.
Target Agents On First Line Therapy Of Advanced HER2-positive Breast Cancer:A Network Meta-analysis
51.
Detection Of HER2 Positive Circulating Tumor Cell By Using Anti-HER2-renilla Luciferase Fusion Protein
52.
Preoperative Dose-dense Chemotherapy Or Postoperative Chemotherapy For Operative Triple Negative Or HER2-positive Breast Cancer:A Randomized Study
53.
Different Expression Of Long-non Coding RNA In Her2 Positive Gastric Cancer
54.
HER2 Positive Bilateral Metachronous Primary Breast Carcinoma: A Case Report And Literature Review
55.
Study On The Mechanism Underlying Valproic Acid Reversed Trastuzumab Resistance In HER2-positive Breast Cancer Cells
56.
The Analysis Of Diagnosis And Treatment In HER2 Positive Breast Cancer
57.
Therapeutic Evaluation Of HER2-positive Breast Cancer With Neoadjuvant Chemotherapy Combined With Targeted Therapy
58.
Trastuzumab Treatment After Progression In HER2-positive Metastatic Breast Cancer Following Relapse Of Trastuzumab-based Regimens
59.
Prognostic Analysis Of HER2 Positive Metastatic Breast Cancer And Establishment Of Prognostic Model
60.
The Expression And Heterogeneity Analysis Of PD-1/PD-L1 In Triple-negative Breast Cancer And The Clinical Significance Of TIL
<<First
<Prev
Next>
Last>>
Jump to